The excitement around Moderna’s cancer vaccine is cooling. Here’s why.

Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketwatch.com)